Michael Rafii

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Recent developments in Alzheimer's disease therapeutics
    Michael S Rafii
    Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
    BMC Med 7:7. 2009
  2. ncbi The pulse of drug development for Alzheimer's disease
    Michael S Rafii
    Alzheimer s Disease Cooperative Study, Attending Neurologist, Shiley Marcos Alzheimer s Disease Research Center, University of California, San Diego, USA
    Rev Recent Clin Trials 5:57-62. 2010
  3. ncbi Comparison of the memory performance index with standard neuropsychological measures of cognition
    Michael Rafii
    Shiley Marcos Alzheimer s Disease Research Center and the Department of Neurosciences, University of California, San Diego, CA, USA
    Am J Alzheimers Dis Other Demen 26:235-9. 2011
  4. ncbi A phase II trial of huperzine A in mild to moderate Alzheimer disease
    M S Rafii
    Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA
    Neurology 76:1389-94. 2011
  5. ncbi High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment
    Sanja Kovacevic
    Department of Radiology, University of California, San Diego, La Jolla, CA 92093 094, USA
    Alzheimer Dis Assoc Disord 23:139-45. 2009

Collaborators

Detail Information

Publications5

  1. ncbi Recent developments in Alzheimer's disease therapeutics
    Michael S Rafii
    Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
    BMC Med 7:7. 2009
    ..In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed...
  2. ncbi The pulse of drug development for Alzheimer's disease
    Michael S Rafii
    Alzheimer s Disease Cooperative Study, Attending Neurologist, Shiley Marcos Alzheimer s Disease Research Center, University of California, San Diego, USA
    Rev Recent Clin Trials 5:57-62. 2010
    ..In this review, the current status of Alzheimer's Disease therapies under study is discussed, including the scientific basis for each strategy...
  3. ncbi Comparison of the memory performance index with standard neuropsychological measures of cognition
    Michael Rafii
    Shiley Marcos Alzheimer s Disease Research Center and the Department of Neurosciences, University of California, San Diego, CA, USA
    Am J Alzheimers Dis Other Demen 26:235-9. 2011
    ..The MCIS may be a valuable tool in the identification of elderly at high risk for dementia due to its ease-of-use and brief administration time...
  4. ncbi A phase II trial of huperzine A in mild to moderate Alzheimer disease
    M S Rafii
    Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA
    Neurology 76:1389-94. 2011
    ..Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD)...
  5. ncbi High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment
    Sanja Kovacevic
    Department of Radiology, University of California, San Diego, La Jolla, CA 92093 094, USA
    Alzheimer Dis Assoc Disord 23:139-45. 2009
    ..Fully automated and rapid measurement of segmental MTL volumes may help clinicians predict clinical decline in MCI patients...